COMMUNIQUÉS West-GlobeNewswire

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
06/02/2025
VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
06/02/2025
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement [...]
e-therapeutics présentera des données précliniques relatives à l’ETX-148 lors de l’édition 2025 du Congrès annuel de l’EAHAD
05/02/2025
LONDRES, 05 févr. 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, une entreprise qui conjugue la puissance informatique aux données biologiques en vue de mettre au point des nouveaux médicaments ARNi, annonce ce jour son [...]
STERIS Announces Financial Results for Fiscal 2025 Third Quarter
05/02/2025
Total revenue from continuing operations increased 6%; constant currency organic revenue grew 6% As reported diluted EPS from continuing operations increased to $1.75; adjusted EPS increased to $2.32 Fiscal 2025 outlook [...]
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
05/02/2025
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office [...]
DLH Reports Fiscal 2025 First Quarter Results
05/02/2025
Navigating Challenges in Company's Transformation Journey; Delivering Recent Wins and Growing Bid Pipeline to Improve Outlook for Organic Growth ATLANTA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: [...]
The Ensign Group Reports Fiscal Year and Fourth Quarter 2024 Results; Issues 2025 Earnings Guidance
05/02/2025
Conference Call and Webcast scheduled for tomorrow, February 6, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign [...]
BriaCell Therapeutics Announces Closing of Public Offering
05/02/2025
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
05/02/2025
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
05/02/2025
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
05/02/2025
FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
05/02/2025
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
05/02/2025
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular [...]
Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update
05/02/2025
Enhanced liquidity by $27.5 million through the issuance of 6.9 million common shares First quarter fiscal 2025 revenue declined 11.5% to $119.9 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, [...]
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
05/02/2025
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated with no serious [...]
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
05/02/2025
TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“ NurExone ” or the “ Company ”) is pleased to announce the formation of a U.S.-based [...]
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
05/02/2025
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog [...]
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
05/02/2025
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, [...]
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
05/02/2025
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track for 2Q 2025 – – [...]

Pages